Publication | Open Access
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
10
Citations
15
References
2022
Year
ClinicalTrials.gov, NCT03293108 ; Registration date: 2017-09-19.
| Year | Citations | |
|---|---|---|
Page 1
Page 1